Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy

Rheumatology

Volumn 42, Issue 5, 2003, Pages 617-621

  Kroesen, S ^a   Widmer, A F ^a   Tyndall, A ^a   Hasler, Paul ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Rheumatologische Universitatsklinik und Poliklinik   (Switzerland)

Author keywords

Anti TNF therapy; Complications; Infection; Rheumatoid arthritis; TNF

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; DICLOFENAC; ETANERCEPT; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEPSIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FOLLOW UP; IMMUNE DEFICIENCY; IMMUNOLOGY; MIDDLE AGED; OPPORTUNISTIC INFECTION; PROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042027086     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg263     Document Type: Article

References (12)

1. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) vs placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group; Lancet 1999; 354:1932-9.
2. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
3. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
4. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
5. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.
6. van den Borne BE, Landewe RB, Houkes I et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1930-7.
7. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002;46:2287-93.
8. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
9. Uitz E, Fransen J, Langenegger T, Stucki G. Clinical quality management in rheumatoid arthritis: putting theory into practice. Rheumatology 2000;39:542-9.
10. Castro JG, Dowdy L. Septic shock caused by Staphylococcus lugdunensis. Clin Infect Dis 1999;28:681-2.
11. Riegels-Nielsen P, Jensen JS. Septic arthritis of the knee. Five cases treated with synovectomy. Acta Orthop Scand 1984;55:657-9.
12. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.